Domperidone and Ventricular Arrhythmia or Sudden Cardiac Death

@article{Noord2010DomperidoneAV,
  title={Domperidone and Ventricular Arrhythmia or Sudden Cardiac Death},
  author={Charlotte van Noord and Jeanne P. Dieleman and Gerard van Herpen and Katia M.C. Verhamme and iriam C. J. M. Sturkenboom},
  journal={Drug Safety},
  year={2010},
  volume={33},
  pages={1003-1014}
}
AbstractBackground: Recently, a 4-fold increase in risk of sudden cardiac death (SCD) was reported for domperidone in a study that focused on corrected QT interval (QTc)-prolonging drugs as a class and their association with SCD. Objective: To evaluate the association between the use of domperidone and serious non-fatal ventricular arrhythmia (VA) and SCD in the general population. Methods: We performed a population-based, case-control study during 1996–2007 in the Integrated Primary Care… Expand
A case of sudden cardiac death following Domperidone self-medication.
TLDR
The forensic implications of D administration are discussed focusing on issues related to the self-administration as an OTC drug, administration to incapacitated subjects, prescription to patients with contraindications and the off-label drug use of D at high and hazardous concentrations to stimulate lactation. Expand
Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease
TLDR
Domperidone use may increase the risk of ventricular tachyarrhythmia and sudden cardiac death (VT/SCD) in patients with PD, particularly those with a history of cardiovascular disease. Expand
Risk of domperidone induced severe ventricular arrhythmia
TLDR
Domperidone, mosapride, or itopride use is associated with an increased risk of severe VA, however, the magnitude of association was modest and dom peridone use does not increase further the risk, compared with other prokinetics. Expand
[Cardiac adverse effects of domperidone in adult patients: a systematic review].
TLDR
Evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults and a significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Expand
Domperidone: Limited Benefits With Significant Risk for Sudden Cardiac Death
  • L. Hondeghem
  • Medicine
  • Journal of cardiovascular pharmacology
  • 2013
TLDR
Because domperidone has placebo-like benefits but is associated with increased SCD and a narrow safety margin, it should not be used in medicine. Expand
Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death
TLDR
Wide use of domperidone should best be restricted to patients in whom its benefits are proven to justify the risks, and availability without prescription and advertising as an ‘innocent’ relief is incorrect and unsafe, and needs to be reconsidered. Expand
Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study
TLDR
Compared with non-use of any study drug, current domperidone use was associated with sudden cardiac death in nested case-control and case-crossover analyses, with a suggestion of higher risk in older persons and users of higher daily doses. Expand
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
TLDR
Evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults, and a significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Expand
Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review.
TLDR
Given gaps in the literature, use of domperidone for patients undergoing dialysis should be assessed on a case-by-case basis and extreme caution should be used for patients taking more than 30 mg/day of this drug. Expand
Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis
TLDR
Evidence from this meta-analysis suggests that current dom peridone use increases the risk of cardiac arrhythmia and sudden cardiac death by 70 %. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.
TLDR
The use of non-cardiac QTc-prolonging drugs in a general population is associated with an increased risk of sudden cardiac death. Expand
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults.
TLDR
Abnormal QTc prolongation on the electrocardiogram should be viewed as an independent risk factor for sudden cardiac death. Expand
Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders
TLDR
Domperidone possesses cardiac electrophysiological effects similar to those of cisapride and class III antiarrhythmic drugs, and should not be considered a no-risk alternative to cisAPride, a drug that was recently withdrawn from the US market. Expand
Drug induced QT prolongation and torsades de pointes
TLDR
In 1966, Francois Dessertenne described a specific electrocardiographic form of polymorphic ventricular tachycardia, which he termed “torsades de pointes” (TdP) and, until recently, there has been considerable conjecture as to the pathophysiology of this arrhythmia. Expand
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
TLDR
The dataset confirms the widely-held belief that most drugs associated with TdP in humans are also associated with hERG K(+) channel block at concentrations close to or superimposed upon the free plasma concentrations found in clinical use. Expand
Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community.
TLDR
Sudden cardiac death accounts for 5.6% of annual mortality, and prospective evaluation in the general population appears to be feasible, and the use of multiple sources of ascertainment and information significantly enhances phenotyping of SCD cases. Expand
Drug-induced prolongation of the QT interval.
  • D. Roden
  • Medicine
  • The New England journal of medicine
  • 2004
The single most common cause of the withdrawal or restriction of the use of marketed drugs has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or torsade deExpand
What clinicians should know about the QT interval.
TLDR
Although the use of QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of information that can help clinicians and patients make optimal informed decisions about how to minimize the risk of this serious complication. Expand
Task Force on Sudden Cardiac Death of the European Society of Cardiology.
TLDR
The members of the Task Force on Sudden Death dedicate this paper to the memory of their former friend and colleague, Professor Ronald W. F. Campbell, who spent his life working in the field of sudden cardiac death, and the extent of the expanding knowledge in this field is described. Expand
International primary care classifications: the effect of fifteen years of evolution.
To better understand the development of primary care classifications over the past 15 years, 10 primary care databases have been retrospectively analysed using the structure of the InternationalExpand
...
1
2
...